Brind.

Neurocrine Biosciences and AbbVie collaborated on treatments for chorea associated with Huntington's disease.

2 reports, 1 independent Updated Aug 7

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Neurocrine Biosciences and AbbVie collaborated on treatments for chorea associated with Huntington's disease.

Who's involved

What this event is mainly about

Neurocrine Biosciences AbbVie Huntington

Keep exploring

The entities involved

Neurocrine Biosciences
American biopharmaceutical company

Nothing else this week.
AbbVie
pharmaceutical company
- MarketBeat's screener has identified a list of dividend stocks.Sun 22:22
- AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.Sun 13:48
Huntington
station on the Long Island Rail Road in New York, USA

Nothing else this week.

Related events

AbbVie and Cerevel Therapeutics successfully launched a new drug for Parkinson's disease, pending government coverage negotiations.Sat 07:08

Coverage

Newest first; wire copies grouped

Aug 7PR NewswireNeurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference SAN DIEGO, Aug. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Ca
Jul 10PR NewswireNeurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results Conference Call and Webcast Scheduled for Wednesday, July 30 SAN DIEGO, July 9, 2025 /PRNewswire/